This report was first published by Endpoints News. To see the original version, click here
Swiss biotech Windward Bio is picking up a second drug candidate from a China biotech this year, seeking to bring multiple medicines to market for respiratory and dermatology conditions.
Windward is paying up to $700 million to gain access to a TSLP and IL-13 bispecific antibody from Qyuns Therapeutics. The partners declined to disclose the upfront size of the deal but said Qyuns gets an equity stake in Windward. Qyuns’ other bispecific antibody pact this year with Roche came with $70 million upfront.
您已阅读15%（595字），剩余85%（3490字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。